Inactive Instrument

News PHARMING GROUP Euronext Amsterdam

Stocks

NL0000377018

Pharmaceuticals

End-of-day quote Euronext Amsterdam
- ^EUR	-

08-13	Pharming Launches Joenja in Japan for Adult, Pediatric APDS Patients	MT
08-13	Pharming Group Launches Rare Primary Immunodeficiency Therapy Joenja in Japan	MT

All News

Mentions Relevance

08-13	Pharming Launches Joenja in Japan for Adult, Pediatric APDS Patients	MT
08-13	Pharming Group Launches Rare Primary Immunodeficiency Therapy Joenja in Japan	MT
08-13	Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older	GL
08-13	Pharming Group Announces Commercial Launch of Joenja in Japan for Adult and Pediatric Patients with Apds Aged 4 and Older	CI
08-04	Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference	GL
07-30	Pharming Group N.V., Q2 2026 Earnings Call, Jul 30, 2026
07-30	Pharming Group's Q2 Earnings, Revenue Fall; 2026 Revenue Outlook Updated	MT
07-30	Pharming Group N.V. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-30	Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use	GL
07-30	Pharming Group N.V. Revises Earnings Guidance for the Year 2026	CI
07-16	Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30	GL
07-08	Pharming N : DWS Investment GmbH - Pharming Group N.V. - Leiden	PU
07-03	Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden	PU
07-03	Pharming N : DWS Investment GmbH - Pharming Group N.V. - Leiden	PU
06-05	Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja to treat children aged 4 to 11 years with APDS	AQ
06-04	Pharming Group N.V. Announces U.S. FDA Acceptance of sNDA Resubmission for Joenja to Treat Children Aged 4 to 11 Years with APDS	CI
06-04	Pharming Group Says Marketing Application for Immunodeficiency Disorder Drug Accepted by FDA	MT
06-04	US FDA Accepts Pharming Group's Resubmitted Application for Immunodeficiency Treatment	MT
06-04	Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS	GL
06-02	Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York	GL
05-28	Pharming Group announces results of 2026 Annual General Meeting of Shareholders	GL
05-26	Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden	PU
05-24	Pharming Group Receives EU Approval for Rare Primary Immunodeficiency Treatment Joenja	MT
05-22	Pharming Says European Commission Grants Marketing Authorization to Joenja	MT
05-22	European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union	GL